Medtech company Theraclion obtains €8.5 million in R&D funding from OSEO
The €8.5 million in funding comes as a direct, €3.5 million grant and €5 million in reimbursable advances. In all, €6.9 million of the total amount will be attributed to Theraclion, with €1.6 million going to SuperSonic Imagine. After €500,000 in 2005 and €1.3 million in 2007, this is the third time that OSEO has provided Theraclion with financial support.
“We are particularly proud to see that OSEO has given our company a vote of confidence by awarding significant funding for the third time running. We shall pursue our clinical trials (the interim results of which are very convincing) and prepare the forthcoming commercialization of our products. We are the only company in the world to use ultrasound and our "UNIS" method in the treatment of hyperparathyroidism and our strategy is also to explore new clinical applications to broaden our field of opportunities,” says Ismaël Nujurally, CEO, Theraclion.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.